{"entity":{"id":"nct05760378","kind":"trial","name":"Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.","aka":[],"tldr":"A phase 3 trial of camrelizumab, capecitabine, eribulin and carboplatin in triple-negative breast cancer, run by Fudan University, now recruiting.","summary":"Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. is a phase 3, randomised interventional study registered as NCT05760378 by Fudan University, with a registry enrolment figure of 223 participants, started 2023-03-17 and due to reach its primary completion in 2025-01-01. Interventions recorded: Famitinib; Camrelizumab; nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin. Conditions listed: Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"* Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT05760378","url":"https://clinicaltrials.gov/study/NCT05760378"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["camrelizumab","capecitabine","eribulin","carboplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05760378","phase":"3","setting":"An Open, Randomized Phase III Study of Famitinib With Camrelizumab Plus Treatment of Physician's Choice (TPC) Versus Camrelizumab Plus TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic Triple-negative Breast Cancer","sponsor":"Fudan University","enrolled":223,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05760378/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"camrelizumab","kind":"drug","name":"Camrelizumab","route":"/drugs/camrelizumab/"},{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"eribulin","kind":"drug","name":"Eribulin","route":"/drugs/eribulin/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}